The Safety of Hemophilia Gene Therapy Now and in the Future

The Safety of Hemophilia Gene Therapy Now and in the Future

Listen to Michael Makris, MA, MB, MS, MD, FRCP, FRCPath, Director of the Sheffield Hemophilia and Thrombosis Centre, Sheffield, UK, discuss the overall safety of Hemophilia Gene Therapy now and in the future. Earn your CME credit by clicking the box below. This podcast is part of the ISTH (International Society on Thrombosis and Haemostasis) comprehensive educational resource designed by leading experts for the global hemophilia community to help keep you abreast on the evolving science and latest clinical advancements in gene therapy and hemophilia research.

Michael Makris, MA, MB BS, MD, FRCP, FRCPath
Michael Makris, MA, MB BS, MD, FRCP, FRCPath
Director, Sheffield Hemophilia and Thrombosis Centre
Sheffield, United Kingdom

Michael Makris, MA, MB BS, MD, FRCP, FRCPath, is Director of the Sheffield Hemophilia and Thrombosis Centre, Sheffield, UK. He trained in Medicine and Hematology at the Universities of Oxford, London and Sheffield in the United Kingdom. Dr. Makris is Professor of Hemostasis and Thrombosis at the University of Sheffield and since 1994 he has been an honorary consultant hematologist at The Sheffield Teaching Hospitals NHS Trust in Sheffield, United Kingdom.

Image

Please enable the javascript to submit this form

Supported by educational grants from BioMarin, CSL Behring, Pfizer and Spark Therapeutics

Essential SSL